PanGenetics
Signal active
Organization
Contact Information
Overview
PanGenetics B.V. develops monoclonal antibodies for the treatment of immune mediated diseases.
PanGenetics is a clinical development company that specializes in taking antibodies from the late research stage through to clinical proof of concept. The company is based in Utrecht, the Netherlands with an office in Cambridge, UK. PanGenetics employs a lean business model with manufacturing and clinical development activities outsourced to specialist providers. Apart from PG110, the other clinical program of PanGenetics is PG102, a CD40 antagonist for treatment of autoimmune diseases which is currently being evaluated in a clinical study in psoriatic arthritis patients
About
Industries
Pharmaceutical, Manufacturing
Founded
1995
Employees
11-50
Headquarters locations
Europe
Social
N/A
Profile Resume
PanGenetics headquartered in Europe, operates in the Pharmaceutical, Manufacturing sector. The company focuses on Pharmaceutical and has secured $1.3B in funding across 24 round(s). With a team of 11-50 employees, PanGenetics is actively contributing to advancements in Pharmaceutical. Their latest funding round, Series C - PanGenetics, raised $35.1M. Discover more about their projects, partnerships, and impact on our platform.
Employees
N/A
Funding Rounds
Funding rounds
3
Investors
5
Lead Investors
0
Total Funding Amount
$52.7M
Details
3
PanGenetics has raised a total of $52.7M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2006 | Early Stage Venture | 15.6M | ||
| 2005 | Seed | 2.0M | ||
| 2008 | Late Stage Venture | 35.1M |
Investors
PanGenetics is funded by 16 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Index Ventures | - | FUNDING ROUND - Index Ventures | 35.1M |
| Crédit Agricole | - | FUNDING ROUND - Crédit Agricole | 35.1M |
| PanGenetics | - | FUNDING ROUND - PanGenetics | 35.1M |
| Forbion Capital Partners | - | FUNDING ROUND - Forbion Capital Partners | 35.1M |
Recent Activity
There is no recent news or activity for this profile.